Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|1347-9032|9|1202-1211

ISSN： 1347-9032

Source： Cancer Science, Vol.1347-9032, Iss.9, 2015-09, pp. : 1202-1211

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1202-1211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acquisition of cancer stem cell‐like properties in non‐small cell lung cancer with acquired resistance to afatinib

By  

Cancer Science, Vol. 106, Iss. 10, 2015-10 ,pp. : 1377-1384

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of KRAS mutation on response and outcome of patients with stage III non‐squamous non‐small cell lung cancer

By  

Cancer Science, Vol. 106, Iss. 10, 2015-10 ,pp. : 1402-1407

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic value of 18F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer

By  

Cancer Science, Vol. 106, Iss. 11, 2015-11 ,pp. : 1554-1560

John Wiley & Sons Inc

Access to resources Recommend Favorite

ERGIC3, which is regulated by miR‐203a, is a potential biomarker for non‐small cell lung cancer

By  

Cancer Science, Vol. 106, Iss. 10, 2015-10 ,pp. : 1463-1473

John Wiley & Sons Inc

Access to resources Recommend Favorite